A significant setback for ArriVent BioPharma has sent its stock price into a tailspin, following the disappointing results of its pivotal Phase III FURVENT trial for firmonertinib in non-small cell lung cancer (NSCLC). The investigational drug, designed to target a notoriously difficult-to-treat subset of NSCLC patients with EGFR exon 20 insertion mutations, failed to achieve its primary endpoint of progression-free survival (PFS). This news arrives in the shadow of a recent triumph for competitor Johnson & Johnson in the same patient population, intensifying the pressure on ArriVent and highlighting the fierce competition within the oncology drug development arena.
The FURVENT trial (NCT05607550) evaluated firmonertinib as a monotherapy for patients with previously untreated, locally advanced or metastatic non-squamous NSCLC harboring EGFR exon 20 insertion mutations. These specific mutations, while accounting for approximately 12% of all EGFR mutations in NSCLC, have historically posed a significant challenge for targeted therapies, often leading to poorer prognoses and limited treatment options.
Trial Outcomes: A Disappointing Primary Endpoint
The trial’s primary endpoint, progression-free survival (PFS) as assessed by blinded independent central review (BICR), was not met. The data revealed median PFS figures of 11 months in the 240mg cohort and 8.4 months in the 160mg cohort of firmonertinib. Crucially, these results were compared against a control group receiving platinum-based chemotherapy with pemetrexed, the current first-line standard of care (SoC) for this patient population, which demonstrated a median PFS of 9.5 months.
While the primary endpoint was not achieved, ArriVent did report observing clinical benefit in secondary endpoints. These included improvements in PFS as assessed by investigator review and a confirmed objective response rate (ORR) by BIC. Furthermore, although not yet mature, a trend towards an improvement in overall survival (OS) was also noted. The safety profile of firmonertinib in the FURVENT trial was consistent with findings from previous clinical studies, with no new safety signals identified, suggesting the drug’s tolerability was maintained.
Chronology of Disappointment and Market Reaction
The repercussions of the FURVENT trial’s outcome were swift and severe. Following the announcement of the data, ArriVent BioPharma’s stock experienced a dramatic plunge. The share price plummeted from $28.46 at market close on October 5th to a mere $12.09 at the market open on October 6th. While there was a slight recovery during the trading day, the stock ultimately closed at $15.09, representing a substantial 46.98% drop in value day-on-day. This significant market reaction underscores the high expectations placed on firmonertinib and the profound impact of failing to meet a critical clinical trial milestone. ArriVent, a Nasdaq-listed company, saw its market capitalization shrink considerably in the wake of this news.
Firmonertinib: Profile and Potential
Firmonertinib is characterized as an oral, brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor. Its mechanism of action is designed to target both classical and uncommon EGFR mutations, including the challenging PACC and exon 20 insertion mutations. The drug has already achieved regulatory approval in China for first-line NSCLC in March 2021. Furthermore, it has garnered significant regulatory attention in the United States, having been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. It also holds Orphan Drug Designation for its use in NSCLC patients with EGFR, HER2, or HER4 mutations.
Beyond the now-disappointing FURVENT trial, ArriVent is also pursuing further development of firmonertinib in a second global Phase III study, ALPACCA (NCT07185997), which is investigating the drug in first-line NSCLC patients with EGFR PACC mutations.
The Competitive Landscape: A Stark Contrast
The disappointing news for ArriVent is amplified by the recent positive readout from Johnson & Johnson (J&J) in the very same patient population. Just weeks prior to ArriVent’s announcement, J&J revealed that its drug, Rybrevant (amivantamab-vmjw), in combination with chemotherapy, demonstrated the longest median overall survival (OS) observed in a Phase III trial targeting NSCLC patients with EGFR exon 20 insertion mutations.
This success for Rybrevant builds upon the primary PAPILLON trial analysis, which had already shown a statistically significant and clinically meaningful 60% improvement in PFS when Rybrevant was added to chemotherapy. In that analysis, the median PFS in the triplet arm reached 11.4 months, a notable improvement over the 6.7 months seen in the doublet chemotherapy arm. The concurrent positive OS data from J&J further solidifies Rybrevant’s position as a leading contender in this challenging NSCLC subtype.
Expert and Official Responses: Navigating the Setback
Dr. Bing Yao, CEO of ArriVent, expressed his company’s disappointment while acknowledging the drug’s consistent safety profile. "While the safety profile observed with firmonertinib was consistent with previous clinical studies, FURVENT did not show a meaningful improvement in PFS over chemotherapy by BICR in this study," Dr. Yao stated. He continued, "We are deeply grateful to the patients, investigators, and clinical teams who made this program possible and are evaluating the full FURVENT dataset as we determine the most appropriate development path for firmonertinib." This measured response indicates that ArriVent is not entirely abandoning the drug but is undertaking a thorough review of the comprehensive trial data before charting its future course.
The failure of firmonertinib to meet its primary endpoint in the FURVENT trial underscores the inherent risks and complexities of drug development, particularly in oncology. The unmet need for effective treatments for EGFR exon 20 insertion mutated NSCLC remains significant. Historically, patients with these mutations have faced grim prognoses, with median OS typically ranging from 16 to 24 months and a five-year survival rate of just 8%.
Broader Market and Future Implications
The NSCLC therapeutics market is a substantial and rapidly growing segment of the pharmaceutical industry. According to a GlobalData report, the market across the seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $24.1 billion in 2022 and is projected to expand to $56.5 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.9%. This robust market growth highlights the ongoing demand for innovative and effective treatments for lung cancer.
The contrasting fortunes of ArriVent and Johnson & Johnson in this specific NSCLC subtype serve as a potent reminder of the competitive nature of the pharmaceutical landscape. For ArriVent, the FURVENT trial results represent a significant hurdle, necessitating a strategic reassessment of firmonertinib’s development trajectory. The company must now weigh the potential of its observed secondary endpoints and the drug’s established safety profile against the unmet bar of its primary objective.
The broader implications extend beyond ArriVent. This outcome may prompt other companies developing therapies for EGFR exon 20 insertion mutations to scrutinize their own trial designs and data with increased vigilance. The success of Rybrevant, on the other hand, solidifies its position and potentially sets a higher benchmark for future therapies aiming to gain traction in this challenging patient population. As the oncology field continues its relentless pursuit of improved patient outcomes, such clinical trial results, whether positive or negative, play a crucial role in shaping the future of cancer treatment. The path forward for firmonertinib, and for ArriVent, will depend on a meticulous analysis of the FURVENT data and a strategic navigation of the evolving competitive and regulatory environment.
About the Author
